| Bioactivity | TT-OAD2 is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 has the potential for diabetes treatment[1][2]. |
| Target | EC50: 5 nM (GLP-1 receptor) |
| Invitro | TT-OAD2 (0-10 μM) inhibits GLP-1- and oxyntomodulin-mediated cAMP, calcium, pERK1/2 and β-arrestin responses in a concentration-dependent manner in HEK293A cells[1]. |
| In Vivo | TT-OAD2 (3 mg/kg; intravenous injection; male human GLP-1 receptor knock-in and knockout mice) treatment induces plasma insulin in an acute IVGTT on humanized GLP-1R knock-in (KI) and GLP-1R knockout (KO) mice[1]. Animal Model: |
| Name | TT-OAD2 |
| CAS | 2382719-60-8 |
| Formula | C50H49Cl4N3O6 |
| Molar Mass | 929.75 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Zhao P, et al. Activation of the GLP-1 receptor by a non-peptidic agonist. Nature. 2020 Jan;577(7790):432-436. [2]. Transtech Pharma, et al. Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof. WO2010114824A1. |
TT-OAD2
CAS: 2382719-60-8 F: C50H49Cl4N3O6 W: 929.75
TT-OAD2 is a non-peptide glucagon-like peptide-1 (GLP-1) receptor agonist with an EC50 of 5 nM. TT-OAD2 has the potentia
Sales Email：peptidedb@qq.com
This product is for research use only, not for human use. We do not sell to patients.